BioPorto and Roche Diagnostics sign a distribution agreement for NGAL
February 09 2018 - 2:22AM
BioPorto and Roche Diagnostics sign a distribution agreement for
NGAL
BioPorto A/S (“BioPorto”) has entered into a global distribution
agreement with Roche, under which BioPorto will deliver a
neutrophil gelatinase-associated lipocalin (NGAL) test for use on
Roche’s cobas c 501/c 502 analysers.
The agreement has significant strategic
importance to ensure the expanded availability of NGAL tests, as
well as enhancing the awareness of NGAL as a diagnostic marker for
acute kidney injury. BioPorto expects the agreement to generate
revenue starting in 2019.
Under the terms of the agreement, Roche will
have worldwide exclusive distribution rights for the NGAL test
adapted for use on Roche’s cobas c 501/c 502 systems.
The NGAL Test™ is CE marked and BioPorto is
currently conducting clinical studies to generate data for FDA
approval, which is expected later this year.
Peter Mørch Eriksen, CEO of BioPorto, said "I am
very happy to enter into a collaboration with Roche, who as a
dominant player in the diagnostic space will ensure a broad global
distribution of our NGAL test to address a critical need in patient
care today.”
For further information, please
contact:Peter Mørch Eriksen, CEOGry Husby Larsen, General
CounselTelephone +45 4529 0000, e-mail investor@bioporto.com
The kidney biomarker NGALEvery year about 13
million people are affected by acute kidney injury worldwide, of
which about 4 million die. Nevertheless, there has been no real
progress in methods of diagnosing kidney injury over the last half
century. Existing methods such as serum creatinine determination,
only signal kidney failure 24-72 hours after the injury has taken
place. In contrast, NGAL rises to diagnostic levels within a few
hours of kidney injury and thus enables the physician to make vital
clinical decisions before the damage progresses to potentially
fatal renal shutdown. In addition to helping the patient,
cost-benefit analyses show that implementing NGAL testing will
contribute to reducing hospital costs in the management of kidney
injury and its consequences.
About BioPortoBioPorto Diagnostics A/S is an
in-vitro diagnostics company that provides healthcare professionals
in clinical and research settings a range of diagnostic tests and
antibodies. Our pioneering product portfolio includes assays for
underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales
channels and partners. BioPorto has its headquarters in Copenhagen,
Denmark and is listed on the NASDAQ Copenhagen stock exchange.
http://prlibrary-eu.nasdaq.com/Resource/Download/5530efef-9b7e-4a45-ae52-199ef29dce7a
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Apr 2023 to Apr 2024